Featured Research

from universities, journals, and other organizations

Research defines timeframes, factors to deem early stage lung cancer cured

Date:
August 2, 2010
Source:
International Association for the Study of Lung Cancer
Summary:
In patients with non-small cell lung cancer, five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: when can cure be declared with confidence and for how long should follow-up examination be continued?

In patients with non-small cell lung cancer (NSCLC), five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: (1) When can cure be declared with confidence and (2) for how long should follow-up examination be continued?

In order to define a strategy for long-term follow-up for early stage lung cancer patients, research published in the August edition of the Journal of Thoracic Oncology (JTO) quantified the risk of late recurrence in patients with stage IA NSCLC who remained recurrence-free for more than five years after complete tumor resection. Overall, the findings indicate that in patients with stage IA NSCLC without vascular invasion (cancer cells within blood vessels), five years may be sufficient to declare that the patients are cured. In contrast, patients with stage IA NSCLC with vascular invasion need follow-up until at least nine years after resection.

In this study, the research team identified a total of 519 patients with stage IA NSCLC who underwent complete resection between August 1992 and December 2002. Recurrence-free probability was measured from the benchmark of five years after primary tumor resection to the date of first recurrence or last follow-up. Of the 519 patients, 434 remained recurrence-free for the first five years. Among these, only 21 (4.8 percent) developed late recurrence more than five years after resection.

The researchers identified one independent significant predictor of late recurrence in stage IA five-year recurrence-free survivors: the presence of vascular invasion. The five-year recurrence-free probability from the benchmark was 84 percent for patients with vascular invasion and 95 percent for patients without vascular invasion.

Summarizing the findings, lead investigator, Ryo Maeda, MD, explains that "If they are recurrence-free, patients without vascular invasion may be declared cured at five years after resection. On the other hand, patients with stage IA NSCLC with vascular invasion, five years without recurrence is not sufficient to conclude that NSCLC is cured."


Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer. Note: Materials may be edited for content and length.


Cite This Page:

International Association for the Study of Lung Cancer. "Research defines timeframes, factors to deem early stage lung cancer cured." ScienceDaily. ScienceDaily, 2 August 2010. <www.sciencedaily.com/releases/2010/08/100802131130.htm>.
International Association for the Study of Lung Cancer. (2010, August 2). Research defines timeframes, factors to deem early stage lung cancer cured. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/08/100802131130.htm
International Association for the Study of Lung Cancer. "Research defines timeframes, factors to deem early stage lung cancer cured." ScienceDaily. www.sciencedaily.com/releases/2010/08/100802131130.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins